Your browser doesn't support javascript.
loading
INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
Van Den Bent, Martin; Eoli, Marica; Sepulveda, Juan Manuel; Smits, Marion; Walenkamp, Annemiek; Frenel, Jean-Sebastian; Franceschi, Enrico; Clement, Paul M; Chinot, Olivier; De Vos, Filip; Whenham, Nicolas; Sanghera, Paul; Weller, Michael; Dubbink, H J; French, Pim; Looman, Jim; Dey, Jyotirmoy; Krause, Scott; Ansell, Pete; Nuyens, Sarah; Spruyt, Maarten; Brilhante, Joana; Coens, Corneel; Gorlia, Thierry; Golfinopoulos, Vassilis.
Afiliação
  • Van Den Bent M; Brain Tumor Institute Erasmus Medical Center (MC) Cancer Institute, Rotterdam, the Netherlands.
  • Eoli M; Department of Neurology, Carlo Besta Institute, Milan, Italy.
  • Sepulveda JM; University Hospital 12 October, Madrid, Spain.
  • Smits M; Department of Radiology, Erasmus MC, Rotterdam, the Netherlands.
  • Walenkamp A; Department of Medical Oncology, University Medical Center Groningen, Groningen, the Netherlands.
  • Frenel JS; Department of Medical Oncology, René Gauducheau Center for Cancer Care, Nantes, France.
  • Franceschi E; Department of Medical Oncology, Local Health Unit Agency/Scientific Institute for Research, Hospitalization, and Healthcare (AUSL/IRCCS) Neurological Sciences, Bologna, Italy.
  • Clement PM; Department of Medical Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.
  • Chinot O; Department of Neuro-Oncology, Institute of Neurophysiopathology, Aix-Marseille University, Marseille, France.
  • De Vos F; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Whenham N; Department of Medical Oncology, European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium.
  • Sanghera P; University Hospitals Birmingham, Birmingham, UK.
  • Weller M; Department of Neurology, University Hospital Zurich, Zurich, Switzerland.
  • Dubbink HJ; Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • French P; Brain Tumor Institute Erasmus Medical Center (MC) Cancer Institute, Rotterdam, the Netherlands.
  • Looman J; Abbvie, Chicago, IL USA.
  • Dey J; Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
  • Krause S; Abbvie, Chicago, IL USA.
  • Ansell P; Abbvie, Chicago, IL USA.
  • Nuyens S; Abbvie, Chicago, IL USA.
  • Spruyt M; EORTC Headquarters, Brussels, Belgium.
  • Brilhante J; Brain Tumor Institute Erasmus Medical Center (MC) Cancer Institute, Rotterdam, the Netherlands.
  • Coens C; EORTC Headquarters, Brussels, Belgium.
  • Gorlia T; EORTC Headquarters, Brussels, Belgium.
  • Golfinopoulos V; EORTC Headquarters, Brussels, Belgium.
Neuro Oncol ; 22(5): 684-693, 2020 05 15.
Article em En | MEDLINE | ID: mdl-31747009
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Neuro Oncol Assunto da revista: NEOPLASIAS / NEUROLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Holanda
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Neuro Oncol Assunto da revista: NEOPLASIAS / NEUROLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Holanda